Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_4
1
33%
Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(1)
Other(2)

Detailed Status

unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 41 (33.3%)
N/A2 (66.7%)

Trials by Status

terminated133%
unknown267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_4

Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)

NCT03743103
unknownnot_applicable

Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI

NCT03406832
unknownnot_applicable

Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI

NCT03406819

Clinical Trials (3)

Showing 3 of 3 trials
NCT03743103Phase 4

Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)

Terminated
NCT03406832Not Applicable

Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI

Unknown
NCT03406819Not Applicable

Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3